Chris Cain

bio wrapper

headshot column

bio sketch column

Chris joined Apple Tree Partners in 2016 as an Associate focused on therapeutics. Prior to joining Apple Tree, Chris was an Associate at RA Capital Management, LLC, a crossover fund invested in healthcare and the life sciences. Previously, Chris was a writer and editor at BioCentury Publications and the Science-Business eXchange (SciBX), a translational science journal co-published with Nature Publishing Group, where he evaluated the clinical and commercial potential of novel molecular targets and drug platforms emerging from academic labs. Prior to BioCentury, Chris was a researcher at the UCSF, where his work focused on understanding the transcriptional regulation and evolution of morphological change in fungi including the pathogen Candida albicans.

Chris holds a BA in Biology from the UC Santa Barbara. He earned his PhD in Biochemistry and Molecular Biology from the UCSF, where he was awarded a Genentech Graduate Fellowship.